Semaglutide Alcohol Use Disorder Trial Enrolls 622 Veterans

What the VA semaglutide alcohol use disorder trial will test

A record added to ClinicalTrials.gov on August 4, 2026 describes a randomized, double-blind, placebo-controlled phase 3 trial of semaglutide in US veterans with moderate to severe alcohol use disorder. The sponsor is the VA Office of Research and Development, the registration number is NCT07218354, the planned enrollment is 622 participants, and the status is recruiting.

Per the registration, qualifying participants are randomly assigned to semaglutide injections or placebo injections over a 28-week treatment period, followed by a four-week post-treatment safety assessment window. The protocol uses a gradual escalation approach, with the amount increased in steps as tolerated up to a maximum specified in the protocol. Its stated purpose is to gather evidence on effectiveness for alcohol use disorder, which the record frames as a potentially "new and more appealing treatment option."

Scale is what distinguishes this from earlier work. Trials of medications for alcohol use disorder are often measured in dozens of participants; a 622-person randomized phase 3 with a placebo arm is the design regulators and guideline committees take seriously, and it is being run in a health system with the infrastructure to follow that many people through weekly injections and structured interviews.

Why is a diabetes and obesity drug being tested for drinking?

Semaglutide is a glucagon-like peptide-1 receptor agonist approved for type 2 diabetes and for chronic weight management under separate brand names. Interest in its effect on alcohol consumption grew out of reports from patients and clinicians and from earlier controlled work, and it has now produced a small pipeline of dedicated trials rather than isolated observations.

The most advanced of those before now is Semaglutide Therapy for Alcohol Reduction, or STAR, registered as NCT06015893 and sponsored by the National Institute on Drug Abuse. It is a phase 2 study with 63 participants, listed as active and no longer recruiting, in which adults with alcohol use disorder were randomly assigned to semaglutide or placebo and attended weekly visits at NIDA in Baltimore for roughly 20 weeks, providing blood, urine and saliva samples along with other assessments.

The VA record is candid about the rationale: medications can help many people reduce drinking, but the number of available options is limited and more are needed. That framing matters when reading results later — the comparison that counts is against placebo and against existing options, not against no treatment at all.

People already on a provider-directed regimen often use a semaglutide dosage calculator to keep their own records consistent with what was prescribed.

How the trial measures success: the Timeline Follow-Back

The primary measure in the VA trial is a reduction in risky drinking, assessed with the Timeline Follow-Back, described in the registration as a well-validated calendar-based interview technique for recording daily alcohol consumption. In practice, a trained interviewer walks a participant back through a defined period day by day, using a calendar and memory anchors to reconstruct how much was consumed on each day.

That choice tells you something about the endpoint. The trial is not measuring abstinence as a single yes-or-no outcome, and it is not relying on a laboratory marker alone; it is measuring a pattern of consumption reconstructed from self-report using a standardised method. The four-week post-treatment safety assessment sits after the randomized period, which is where any signals arising as treatment ends would be captured.

Dated side-effect logging that includes mood, sleep and appetite gives a clinician more to work with than gastrointestinal notes alone.

Observational reports on smoking and mood in people with HIV

Two papers in the journal AIDS, indexed in the same week, come from routine clinical care rather than a trial. One, credited to Ruderman, Crane, Haidar and colleagues, is titled Initiating semaglutide therapy reduces tobacco cigarette smoking intensity among people with HIV — a finding about smoking intensity in a clinical cohort, stated by the authors in the paper's title.

The companion paper, credited to Haidar, Ruderman, Leong and colleagues, is titled Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care. Neuropsychiatric questions have followed the GLP-1 class through regulatory reviews on both sides of the Atlantic, and cohort analyses of depressive symptom scores in people already receiving the drug are one way that question gets addressed outside a randomized trial.

Both are observational and drawn from a specific patient population, which limits what they can establish. People who start semaglutide differ from those who do not in ways that statistical adjustment can reduce but not eliminate, and neither paper is a substitute for the kind of randomized comparison the VA trial is set up to make. The abstracts were not available in the citation records at the time of writing, so effect sizes and cohort details are in the published articles.

Trials that measure behaviour week by week depend on the same discipline as everyday adherence tracking.

What this does not settle

Semaglutide is not approved anywhere for alcohol use disorder, for smoking cessation, or for any other substance use indication. A recruiting phase 3 trial is a step toward answering the question, not an answer, and the VA registration describes a study that has only just opened enrollment for 622 participants with 28 weeks of treatment each.

Timelines follow from that. Enrollment of that size, plus the treatment and follow-up periods, plus analysis, means results are years rather than months away, and a positive result would then have to be assembled into a regulatory submission or clinical guidance before it changed prescribing. In the meantime, any use of a GLP-1 medicine aimed at drinking is off-label and a matter between a patient and a prescriber.

GLP-1 trials keep widening beyond weight and glucose

The addiction trials are part of a broader pattern of incretin research moving into adjacent conditions. Eli Lilly has two phase 3b studies recruiting that pair mirikizumab, an interleukin-targeted biologic used in inflammatory bowel disease, with tirzepatide in patients who also have overweight or obesity: one in moderately to severely active ulcerative colitis with 350 participants, and one in Crohn's disease with 290, both running up to 61 weeks.

A separate Lilly phase 2 study, NCT06897475, is recruiting 240 participants with type 2 diabetes who are not at their HbA1c goal while on a stable regimen of semaglutide or tirzepatide, and testing whether adding the investigational agent LY3457263 improves glycemic control over about nine months. Combination and add-on designs like these indicate that the class is being studied as a platform other drugs are built on top of, not only as monotherapy.